Almost all pharmaceutical companies that I stumble upon have similar characteristics. These characteristics include having some blockbuster drug in the pipeline surrounded by much hype and promise, receiving minimal revenues stemming from a different product that has less potential than the pipeline drug, consistently losing money and burning cash on research and development, and only having enough cash to fund operations until around the date when results of their blockbuster drug are expected to be released. In other words, the company's stock price and valuation is hanging on the passing of the pipeline drug, and can either be a homerun or a strike out. It's a hit or miss.
Tianyvin (NYSEMKT:TPI) is the exact opposite. This Chinese pharmaceutical...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|